Insight Molecular Diagnostics (IMDX) Other Operating Expenses (2015 - 2026)

Insight Molecular Diagnostics has disclosed Other Operating Expenses across 12 years of filings, most recently posting -$3.5 million for Q1 2026.

• Other Operating Expenses for Q1 2026 came in at -$3.5 million, down 268.63% year-over-year; the trailing twelve-month figure through Mar 2026 was $21.3 million (down 46.1% YoY), and the FY2025 annual result was $26.9 million, down 35.58% from the prior year.
• Other Operating Expenses came in at -$3.5 million for Q1 2026 at Insight Molecular Diagnostics, down from $15.8 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $29.4 million in Q4 2024 to a low of -$11.4 million in Q1 2023.
• The 5-year median for Other Operating Expenses is $2.6 million (2023), against an average of $3.5 million.
• Across the five-year window, Other Operating Expenses plunged 330.56% in 2022 and soared 2495.51% in 2025, its largest moves.
• Insight Molecular Diagnostics' Other Operating Expenses stood at $5.2 million in 2022, then jumped by 128.14% to $11.8 million in 2023, then surged by 149.99% to $29.4 million in 2024, then slumped by 46.35% to $15.8 million in 2025, then tumbled by 122.29% to -$3.5 million in 2026.
• The last three Other Operating Expenses figures came in at -$3.5 million (Q1 2026), $15.8 million (Q4 2025), and $4.8 million (Q3 2025), per Business Quant data.